Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omnimen is a multi-ingredient dietary supplement developed by Omnifarma Kiev, specifically formulated to support men's urogenital health. The product contains a synergistic blend of standardized herbal extracts, including Saw Palmetto (*Serenoa repens*), Nettle (*Urtica dioica*), and Pygeum (*Prunus africana*), alongside micronutrients such as Zinc, Selenium, and Lycopene. These components are traditionally used to maintain the functional state of the prostate gland and the lower urinary tract. The mechanism of action involves the inhibition of 5-alpha-reductase and aromatase enzymes, which helps regulate dihydrotestosterone levels and the hormonal balance within prostate tissue. Additionally, the formulation provides anti-inflammatory and antioxidant support, which may alleviate symptoms associated with benign prostatic hyperplasia (BPH) and chronic prostatitis, such as urinary frequency and discomfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Omnimen.